| Literature DB >> 30413663 |
Nicky D'Haene1, Marie Le Mercier2, Isabelle Salmon2, Zita Mekinda3, Myriam Remmelink2, Thierry Berghmans4.
Abstract
The large screening of exons 18 to 21 of the epidermal growth factor receptor (EGFR) gene may lead to the discovery of rare, atypical molecular alterations for which the sensitivity to tyrosine kinase inhibitors (TKIs) remains uncertain. We are reporting a rare exon 18 EGFR mutation (p.E709_710 > D) that confers sensitivity to second-generation EGFR TKI (afatinib), lasting for 1 year. Tumor progression biopsy showed small cell lung cancer transformation, associated with a SMAD4 mutation. KEY POINTS: A rare exon 18 epidermal growth factor receptor mutation with sensitivity to afatinib is reported.Small cell transformation was observed at tumor progression.Acquisition of a SMAD4 mutation was observed at tumor progression. © AlphaMed Press 2018.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30413663 PMCID: PMC6324642 DOI: 10.1634/theoncologist.2018-0016
Source DB: PubMed Journal: Oncologist ISSN: 1083-7159